Vivos (NASDAQ: VVOS) extends Streeterville $4.5M debt-for-equity pact
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Vivos Therapeutics has amended its financing arrangement with Streeterville Capital to gain more time to raise equity and restructure debt. A June 18, 2026 letter agreement extends the deadline to complete a qualifying equity financing of at least $2,600,000 from June 15, 2026 to August 31, 2026.
Under the extended agreement, Streeterville has reaffirmed its commitment to convert up to $4.5 million of outstanding debt into a mix of perpetual, non-convertible preferred stock and common stock, on a dollar-for-dollar basis with equity raised. This structure is intended to support Vivos’ capital-raising plans while shifting part of its obligations from debt into equity.
Positive
- None.
Negative
- None.
Insights
Vivos gains more time to raise equity while a lender reiterates a sizeable debt-for-equity commitment.
Vivos and Streeterville Capital have extended their strategic financing arrangement, pushing the deadline for a qualifying $2,600,000 equity raise to August 31, 2026. Streeterville reiterates its willingness to convert up to $4.5 million of debt into perpetual preferred and common stock.
This structure ties debt conversion directly to new equity raised on a dollar-for-dollar basis, which can reduce leverage if the equity raise succeeds. The company also references a planned rights offering within this window, indicating an intention to involve existing shareholders in the recapitalization efforts.
8-K Event Classification
3 items: 1.01, 7.01, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Qualifying financing threshold: $2,600,000
Debt eligible for conversion: $4.5 million
Extended deadline: August 31, 2026
+2 more
5 metrics
Qualifying financing threshold
$2,600,000
Minimum equity raise required under the agreement
Debt eligible for conversion
$4.5 million
Maximum Streeterville debt to be converted to equity
Extended deadline
August 31, 2026
New outside date to complete qualifying financing
Original deadline
June 15, 2026
Initial outside date before the extension
OSA adult prevalence
Nearly 1 Billion
Estimated adults aged 30–69 affected by OSA worldwide
Key Terms
Material Definitive Agreement, perpetual, non-convertible preferred stock, Regulation FD Disclosure, rights offering, +1 more
5 terms
Material Definitive Agreement regulatory
"Item 1.01 Entry into a Material Definitive Agreement."
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
perpetual, non-convertible preferred stock financial
"convert up to $4.5 million of its outstanding debt into a combination of perpetual, non-convertible preferred stock and shares of common stock"
A perpetual, non-convertible preferred stock is a type of equity that pays a fixed dividend indefinitely and does not mature or convert into common shares. Think of it like buying a permanent seat that pays you a steady rent: it sits above common stock for dividend payments and in liquidation but usually lacks voting rights and upside tied to share price growth. Investors care because it provides predictable income and affects a company’s risk and capital structure without diluting common shareholders.
Regulation FD Disclosure regulatory
"Item 7.01 Regulation FD Disclosure."
Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.
rights offering financial
"to allow the announced rights offering to start during that timeframe."
A rights offering is a way for a company to raise additional money by giving existing shareholders the opportunity to buy more shares at a discounted price before they are offered to the public. It’s similar to a special sale where current owners get the first chance to buy extra items at a lower cost, allowing them to increase their investment if they choose. This process matters to investors because it can affect the value of their holdings and their ability to buy new shares at favorable terms.
forward-looking statements regulatory
"This press release ... contain “forward-looking statements” ... concerning future events."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
What financing deadline did Vivos Therapeutics (VVOS) extend with Streeterville?
Vivos extended the deadline to complete a qualifying equity financing of at least $2.6 million from June 15, 2026 to August 31, 2026. This gives the company more time to organize its capital raise tied to Streeterville’s debt conversion commitment.
How much Streeterville debt can be converted under the Vivos agreement?
Streeterville reaffirmed its commitment to convert up to $4.5 million of outstanding Vivos debt. The conversion will be on a dollar-for-dollar basis with equity Vivos raises, into perpetual, non-convertible preferred stock and common stock of the company.
How is the Vivos–Streeterville debt conversion structured?
The agreement links Streeterville’s debt conversion to Vivos’ equity raise on a dollar-for-dollar basis. Up to $4.5 million of Streeterville’s debt may be converted into a combination of perpetual, non-convertible preferred shares and common stock as Vivos sells new equity.
Why did Vivos Therapeutics seek an extension of the financing agreement?
Vivos concluded the original June 15, 2026 timeframe was too short to complete its planned equity raise. Extending the deadline to August 31, 2026 is intended to allow a more orderly capital-raising process, including time for a planned rights offering to begin.
What type of securities will Vivos issue to Streeterville in the conversion?
Streeterville’s debt is expected to convert into a mix of perpetual, non-convertible preferred stock and common stock of Vivos. This shifts obligations from traditional debt into equity-like instruments tied to the company’s capital structure.
What did Vivos’ CEO say about the Streeterville extension?
CEO R. Kirk Huntsman thanked Streeterville for cooperating on the extension, saying the extra time should help Vivos raise needed equity more systematically and allow its announced rights offering to commence during the extended period while it executes its new strategic business model.